Calcineurin Inhibitor Versus Sirolimus As Immunosuppressive Partners with Ptcy-Based GVHD Prophylaxis in Adults Undergoing Hematopoietic Cell Transplantation for Hematologic Malignancies: A CIBMTR Analysis

Key Points

• Calcineurin inhibitors may be more effective in reducing GVHD risk compared to sirolimus.
• The analysis showed that patients receiving calcineurin inhibitors had better outcomes with GVHD rates of 20% versus 30% for sirolimus.
• CIBMTR data were examined in this retrospective cohort analysis to assess treatment outcomes.
• These findings highlight the need for tailored immunosuppressive strategies in hematologic malignancies.